Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Dermatology | Family Medicine
Metastatic Melanoma Clinical Trials
A listing of Metastatic Melanoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
California
La Jolla : Moores UCSD Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Los Angeles :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Los Angeles : USC Norris Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Colorado
Aurora : University of Colorado Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Florida
Fort Lauderdale : Holy Cross Hospital Updated
MK-3475
View More »
Miami Beach : MSMC Research Program Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Miami Beach : Mount Sinai Medical Center Comprehensive Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Tampa :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Illinois
Chicago : Rush University Medical Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Chicago : Rush Pres St Lukes Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Maywood : Loyola University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Park Ridge : Oncology Specialists, SC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Indiana
Indianapolis : Indiana University Melvin and Bren Simon Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Iowa
Iowa City : University of Iowa Hospitals and Clinics Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Iowa City : University of Iowa Hospitals and Clinics
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Iowa City : University of Iowa Hospitals and Clinics
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Louisiana
Baton Rouge : The Baton Rouge Clinic, AMC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Massachusetts
Boston : Beth Israel Deaconess Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Michigan
Detroit : Karmanos Cancer Institute Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Detroit : Barbara Ann Karmanos Cancer Institute
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Minnesota
Minneapolis : University of Minnesota Masonic Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Minneapolis : University of Minnesota Masonic Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nebraska
Omaha : Midwest Cancer Center - Legacy
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Lebanon : Dartmouth Hitchcock Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
New Jersey
New York
Bronx : Saint Luke's-Roosevelt Hospital Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
North Carolina
Charlotte : Blumenthal Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Durham : Duke University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Winston Salem : Wake Forest University Baptist Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Ohio
Cleveland : Case Comprehensive Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Cleveland : University Hospitals Siedman Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Oregon
Portland : Providence Cancer Center
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Portland : Providence Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Portland : Providence Portland Medical Center
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Portland : Providence Portland Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Pennsylvania
Bethlehem : Saint Luke's Hospital and Health Network
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Easton : St. Luke's Hospital, Anderson Campus Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Philadelphia :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Philadelphia : Fox Chase Cancer Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Pittsburgh : UPMC Cancer Centers Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
View More »
Pittsburgh : Hillman Cancer Research Pavilion, Div. of Medical Oncology
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Tennessee
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville : Vanderbilt-Ingram Cancer Ctr
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Texas
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Houston : MD Anderson Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
San Antonio : The START Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
San Antonio : Cancer Therapy & Research Center at UTHSCSA
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Virginia
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
France
Marseille : Hôpital Sainte Marguerite
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Spain
Pamplona : Local Institution
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
